These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32777068)

  • 21. [Direct Oral Anticoagulants (DOACs): Pharmacological Characteristics and Laboratory Assessment].
    Kitajima I
    Rinsho Byori; 2016 Aug; 64(8):972-979. PubMed ID: 30609341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of reversal agents for direct oral anticoagulants.
    Monagle S; Eikelboom JW; Ng KH; Bhagirath VC
    Future Cardiol; 2017 Mar; 13(2):153-159. PubMed ID: 28198201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
    Kopytek M; Ząbczyk M; Malinowski KP; Undas A; Natorska J
    Clin Chem Lab Med; 2020 Feb; 58(3):430-437. PubMed ID: 31539350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
    Nakazaki M; Oka S; Magota H; Kiyose R; Onodera R; Ukai R; Kataoka-Sasaki Y; Sasaki M; Honmou O
    J Stroke Cerebrovasc Dis; 2022 Jul; 31(7):106520. PubMed ID: 35523052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
    Aungraheeta R; FitzGibbon L; Reilly-Stitt C; Mumford AD
    Int J Lab Hematol; 2020 Apr; 42(2):126-133. PubMed ID: 31756037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A small-molecule hemostatic agent for the reversal of direct oral anticoagulant-induced bleeding.
    Desvages M; Borgel D; Adam F; Tu G; Jaouen S; Reperant C; Denis CV; Desmaële D; Bianchini EP
    Res Pract Thromb Haemost; 2024 May; 8(4):102426. PubMed ID: 38882463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
    Terayama Y
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1171-1181. PubMed ID: 28169097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor Va-factor Xa interactions: molecular sites involved in enzyme:cofactor assembly.
    Steen M
    Scand J Clin Lab Invest Suppl; 2002; 237():5-11. PubMed ID: 12570161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 32. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
    Siriez R; Dogné JM; Gosselin R; Laloy J; Mullier F; Douxfils J
    Int J Lab Hematol; 2021 Feb; 43(1):7-20. PubMed ID: 32946681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct oral anticoagulants: new drugs and new concepts.
    Levy JH; Spyropoulos AC; Samama CM; Douketis J
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes.
    Lucijanic M; Jurin I; Jurin H; Lucijanic T; Starcevic B; Skelin M; Glasnovic A; Catic J; Jurisic A; Hadzibegovic I
    Int J Cardiol; 2020 Feb; 301():90-95. PubMed ID: 31748190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay.
    Kopatz WF; Brinkman HJM; Meijers JCM
    Thromb Res; 2018 Oct; 170():97-101. PubMed ID: 30149286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function.
    Pham P; Schmidt S; Lesko L; Lip GYH; Brown JD
    JAMA Netw Open; 2020 Apr; 3(4):e203593. PubMed ID: 32329770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000.
    Artang R; Brod C; Nielsen JD
    Semin Thromb Hemost; 2022 Oct; 48(7):808-813. PubMed ID: 36174600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.